Choosing and Prioritizing Clinical Trials During the COVID-19 Pandemic

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer post-infection outcomes. In this podcast, Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, chairs an exciting discussion with Jan Philipp Bewersdorf, Yale University and Yale Cancer Center, New Haven, CT, Rory Shallis, MD, Yale University and Yale Cancer Center, New Haven, CT, and John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY. These speakers discuss their recent collaborative publication in Lancet Hematology, evaluating the management of adult patients with acute leukemias and myeloid neoplasms in the COVID-19 era.

The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.